Ricardo A Costa1, Alexandre Abizaid2, Roxana Mehran3, Joachim Schofer4, Gerhard C Schuler5, Karl E Hauptmann6, Marco A Magalhães7, Helen Parise3, Eberhard Grube8. 1. Institute Dante Pazzanese of Cardiology, São Paulo, Brazil; Cardiovascular Research Center, São Paulo, Brazil. Electronic address: rcosta@dantepazzanese.org.br. 2. Institute Dante Pazzanese of Cardiology, São Paulo, Brazil; Cardiovascular Research Center, São Paulo, Brazil. 3. Cardiovascular Research Foundation, New York, New York. 4. Medical Care Center, Hamburg University Cardiovascular Center, Hamburg, Germany. 5. Herzzentrum Leipzig GmbH, Leipzig, Germany. 6. Krankenhaus der Barmherzigen Brüder, Trier, Germany. 7. Cardiovascular Research Center, São Paulo, Brazil. 8. University of Bonn, Bonn, Germany.
Abstract
OBJECTIVES: The purpose of this study was to evaluate the efficacy and long-term outcomes of a novel polymer/carrier-free drug-coated stent (DCS) in patients with de novo coronary lesions. BACKGROUND: The BioFreedom (BFD) DCS incorporates a low-profile, stainless-steel platform, with a surface that has been modified to create a selectively microstructured abluminal surface that allows adhesion and further release of Biolimus A9 (Biosensors Europe SA, Morges, Switzerland). METHODS: A total of 182 patients (183 lesions) were randomized into a 1:1:1 ratio for treatment with BFD "standard dose" (BFD) or BFD "low dose" (BFD-LD) versus first-generation paclitaxel-eluting stents (PES) at 4 sites in Germany. RESULTS: Baseline and procedural characteristics were well matched. At 4-month angiographic follow-up (Cohort 1, n = 75), in-stent late lumen loss (LLL) was significantly lower with BFD and BFD-LD versus PES (0.08 and 0.12 mm vs. 0.37 mm, respectively; p < 0.0001 for BFD vs. PES, and p = 0.002 for BFD-LD vs. PES). At 12 months (Cohort 2, n = 107), in-stent LLL (primary endpoint) was 0.17 mm in BFD versus 0.35 mm in PES (p = 0.001 for noninferiority; p = 0.11 for superiority); however, the BFD-LD (0.22 mm) did not reach noninferiority (p = 0.21). At 5 years (175 of 182), there were no significant differences in major adverse cardiac events (23.8%, 26.4%, and 20.3%) and clinically indicated target lesion revascularization (10.8%, 13.4%, and 10.2%) for BFD, BFD-LD, and PES, respectively; also, there was no definite/probable stent thrombosis reported. CONCLUSIONS: The BFD, but not the BFD-LD, demonstrated noninferiority versus PES in terms of in-stent LLL, a surrogate of neointimal hyperplasia, at 12-month follow-up. At 5 years, clinical event rates were similar, without occurrence of stent thrombosis in all groups. (BioFreedom FIM Clinical Trial; NCT01172119).
RCT Entities:
OBJECTIVES: The purpose of this study was to evaluate the efficacy and long-term outcomes of a novel polymer/carrier-free drug-coated stent (DCS) in patients with de novo coronary lesions. BACKGROUND: The BioFreedom (BFD) DCS incorporates a low-profile, stainless-steel platform, with a surface that has been modified to create a selectively microstructured abluminal surface that allows adhesion and further release of Biolimus A9 (Biosensors Europe SA, Morges, Switzerland). METHODS: A total of 182 patients (183 lesions) were randomized into a 1:1:1 ratio for treatment with BFD "standard dose" (BFD) or BFD "low dose" (BFD-LD) versus first-generation paclitaxel-eluting stents (PES) at 4 sites in Germany. RESULTS: Baseline and procedural characteristics were well matched. At 4-month angiographic follow-up (Cohort 1, n = 75), in-stent late lumen loss (LLL) was significantly lower with BFD and BFD-LD versus PES (0.08 and 0.12 mm vs. 0.37 mm, respectively; p < 0.0001 for BFD vs. PES, and p = 0.002 for BFD-LD vs. PES). At 12 months (Cohort 2, n = 107), in-stent LLL (primary endpoint) was 0.17 mm in BFD versus 0.35 mm in PES (p = 0.001 for noninferiority; p = 0.11 for superiority); however, the BFD-LD (0.22 mm) did not reach noninferiority (p = 0.21). At 5 years (175 of 182), there were no significant differences in major adverse cardiac events (23.8%, 26.4%, and 20.3%) and clinically indicated target lesion revascularization (10.8%, 13.4%, and 10.2%) for BFD, BFD-LD, and PES, respectively; also, there was no definite/probable stent thrombosis reported. CONCLUSIONS: The BFD, but not the BFD-LD, demonstrated noninferiority versus PES in terms of in-stent LLL, a surrogate of neointimal hyperplasia, at 12-month follow-up. At 5 years, clinical event rates were similar, without occurrence of stent thrombosis in all groups. (BioFreedom FIM Clinical Trial; NCT01172119).
Authors: Hendrik Wienemann; Felix Meincke; Marius Vach; Christian-Hendrik Heeger; Annika Meyer; Tobias Spangenberg; Karl Heinz Kuck; Alexander Ghanem Journal: Herz Date: 2022-04-09 Impact factor: 1.443
Authors: Tim Kinnaird; Mehmood Butt; Fairoz Abdul; Khaled Yazji; Ahmed Hailan; Sean Gallagher; Nicholas Ossei-Gerning; Alexander Chase; Anirban Choudhury; David Smith; Richard Anderson Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240
Authors: Deborah N Kalkman; Pier Woudstra; Ian B A Menown; Peter den Heijer; Arnoud Wj Van't Hof; Andrejs Erglis; Harry Suryapranata; Karin E Arkenbout; Andrés Iñiguez; Philippe Muller; Jan G Tijssen; Marcel A M Beijk; Robbert J de Winter Journal: Open Heart Date: 2017-07-11